Activité du Centre National de Référence des Haemophilus influenzae, années 1996–1997: le déclin du type b

Dabernat, H.; Delmas, Catherine

doi:10.1016/s0399-077x(98)80134-0

Cited by 25 publications

(14 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The first observations of ampicillin-resistant non-␤-lactamase producing (BLNAR) strains were reported in the early 1980s and concerned type b capsulated (20, 27) and noncapsulated strains (2, 25). In contrast to the incidence of ␤-lactamase-producing strains, the incidence of BLNAR strains remains low in various countries (4,5,8,32), but in Japan the proportion of BLNAR clinical isolates is more than 25% and seems to be increasing (33,36).In H. influenzae, ampicillin resistance unrelated to ␤-lactamase production was shown to be chromosomally mediated and was correlated with alterations in PBPs 3A and 3B (4,22,29,34). Recently, Ubukata et al (36) demonstrated that mutations in the ftsI gene, which is involved in septal peptidoglycan synthesis, are the most important for the development of resistance to ␤-lactams in BLNAR strains.…”

mentioning

confidence: 99%

“…By far the more frequent is the production of ␤-lactamase, usually of the TEM-1 type but sometimes of the ROB-1 type (15,32). In certain countries, the incidence of strains producing ␤-lactamase is particularly high, reaching 50% in type b strains, which are responsible for invasive manifestations (before anti-Haemophilus b vaccination), and 20 to 30% in noncapsulated strains that lead to bronchopulmonary and ENT infections (5,12,32).…”

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Diversity of β-Lactam Resistance-Conferring Amino Acid Substitutions in Penicillin-Binding Protein 3 of Haemophilus influenzae

Dabernat

Delmas

Seguy

et al. 2002

Antimicrob Agents Chemother

169

153

View full text Add to dashboard Cite

The sequences of the ftsI gene, encoding the transpeptidase domain of penicillin binding protein (PBP) 3A and/or PBP 3B, which are involved in septal peptidoglycan synthesis, were determined for 108 clinical strains of Haemophilus influenzae with reduced susceptibility to ␤-lactam antibiotics with or without ␤-lactamase production and were compared to those of the ampicillin-susceptible Rd strain and ampicillin-susceptible clinical isolates. The sequences have 18 different mutation patterns and were classified into two groups on the basis of amino acid substitutions deduced from the nucleotide sequences located between bp 960 and 1618 of the ftsI gene. In group I strains (n ‫؍‬ 7), His-517 was substituted for Arg-517. In group II strains (n ‫؍‬ 101), Lys-526 was substituted for Asn-526. In subgroup IIa (n ‫؍‬ 5; H. influenzae ATCC 49247), the only observed substitution was Lys-526 for Asn-526; in subgroup IIb (n ‫؍‬ 56), Val-502 was substituted for Ala-502 (n ‫؍‬ In spite of the widespread use of the anti-Haemophilus b vaccine in the industrialized countries and the decreased incidence of invasive diseases (18), Haemophilus influenzae remains a key species in bronchopulmonary and ear, nose, and throat (ENT) infections in both adults and children. These diseases are most often caused by noncapsulated strains (10,14). Treatment of such infections can be severely affected by antibiotic resistance. In H. influenzae resistance to antibiotics, especially to ␤-lactams, has, for a number of years, become a serious problem (6,15,30).Two main mechanisms are at the origin of resistance to aminopenicillins: enzymatic hydrolysis of the antibiotic and a change in penicillin-binding proteins (PBPs). By far the more frequent is the production of ␤-lactamase, usually of the TEM-1 type but sometimes of the ROB-1 type (15,32). In certain countries, the incidence of strains producing ␤-lactamase is particularly high, reaching 50% in type b strains, which are responsible for invasive manifestations (before anti-Haemophilus b vaccination), and 20 to 30% in noncapsulated strains that lead to bronchopulmonary and ENT infections (5, 12, 32).Resistance by mechanisms other than ␤-lactamase production is based on decreased affinity of the PBPs involved in septal peptidoglycan synthesis (4). The first observations of ampicillin-resistant non-␤-lactamase producing (BLNAR) strains were reported in the early 1980s and concerned type b capsulated (20, 27) and noncapsulated strains (2, 25). In contrast to the incidence of ␤-lactamase-producing strains, the incidence of BLNAR strains remains low in various countries (4,5,8,32), but in Japan the proportion of BLNAR clinical isolates is more than 25% and seems to be increasing (33,36).In H. influenzae, ampicillin resistance unrelated to ␤-lactamase production was shown to be chromosomally mediated and was correlated with alterations in PBPs 3A and 3B (4,22,29,34). Recently, Ubukata et al. (36) demonstrated that mutations in the ftsI gene, which is involved in septal peptidoglycan synthesis, are th...

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Diversity of β-Lactam Resistance-Conferring Amino Acid Substitutions in Penicillin-Binding Protein 3 of Haemophilus influenzae

Dabernat

Delmas

Seguy

et al. 2002

Antimicrob Agents Chemother

169

153

View full text Add to dashboard Cite

show abstract

“…In the present analysis, we analysed data on isolates from CSF and/or blood collected by the CNRH from 1991 to 2007 as the mandate of the original CNRH terminated in 2007, and the newly designated CNRH took several months to become operational [9][10][11][12].…”

Section: Data Collectionmentioning

confidence: 99%

Impact ofHaemophilus influenzaetype b vaccination on the incidence of invasiveHaemophilus influenzaedisease in France, 15 years after its introduction

et al. 2013

Self Cite

View full text Add to dashboard Cite

We assessed the impact of Haemophilus influenzae type b (Hib) vaccination, introduced in France in early 1993, on the incidence of invasive Haemophilus influenzae (Hi) disease up to 2008.The incidence of Hi meningitis fell from 0·9/100000 in 1991–1992 to 0·09/100 000 in 1996–2008,with a marked decline (96%) in children aged <5 years, including infants aged <3 months, from 12 to 0·4 /100 000. The incidence of invasive Hi disease also decreased in children aged <15 years from 6 to 0·7 /100 000, remained stable in the 15–64 years age group at about 0·5/100 000,and increased slightly from 2·0 to 2·4 /100 000 in persons aged >64 years. No emergence of non-encapsulated or encapsulated non-vaccine serotypes was observed. These findings confirm the major direct impact of Hib vaccination on the incidence of Hi invasive disease in children and the indirect benefit of vaccination for infants too young to be vaccinated.

show abstract

“…Il est observé chez 26,5 % (215/811) des souches étudiées par le Centre National de Référence des H. influenzae en 2004. Celui-ci est de 22,2 % parmi souches issues de prélèvements ORL (30/135) [194]. Ce mécanisme de résistance rend inactif l'amoxicilline et, à un moindre degré, les céphalosporines de première génération.…”

Section: H Influenzaeunclassified

Antibiothérapie par voie générale en pratique courante dans les infections respiratoires hautes de l'adulte et l'enfant. Argumentaire

2005

Médecine et Maladies Infectieuses

View full text Add to dashboard Cite

Activité du Centre National de Référence des Haemophilus influenzae, années 1996–1997: le déclin du type b

Cited by 25 publications

References 21 publications

Diversity of β-Lactam Resistance-Conferring Amino Acid Substitutions in Penicillin-Binding Protein 3 of Haemophilus influenzae

Diversity of β-Lactam Resistance-Conferring Amino Acid Substitutions in Penicillin-Binding Protein 3 of Haemophilus influenzae

Impact ofHaemophilus influenzaetype b vaccination on the incidence of invasiveHaemophilus influenzaedisease in France, 15 years after its introduction

Antibiothérapie par voie générale en pratique courante dans les infections respiratoires hautes de l'adulte et l'enfant. Argumentaire

Contact Info

Product

Resources

About